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A B S T R A C T
Background: We estimated the potential impact of an investigational 9-valent human papillomavirus
(HPV) vaccine (HPVs 6/11/16/18/31/33/45/52/58) in HPV-related cervical disease in Brazil, Mexico, India
and China, to help to formulate recommendations on cervical cancer prevention and control.
Methods: Estimations for invasive cervical cancer (ICC) were based on an international study including
1356 HPV-positive cases for the four countries altogether, and estimations for precancerous cervical
lesions were extracted from a published meta-analysis including 6 025 HPV-positive women from the
four mentioned countries. Globocan 2012 and 2012 World Population Prospects were used to estimate
current and future projections of new ICC cases.
Results: Combined proportions of the 9 HPV types in ICC were 88.6% (95%CI: 85.2–91.3) in Brazil, 85.7%
(82.3–88.8) in Mexico, 92.2% (87.9–95.3) in India and 97.3% (93.9–99.1) in China. The additional HPV 31/33/
45/52/58 proportions were 18.8% (15.3–22.7) in Brazil, 17.6% (14.2–21.2) in Mexico, 11.3% (7.5–16.1) in
India and 11.9% (7.5–17.2) in China. HPV6 and 11 single types were not identiﬁed in any of the samples.
Proportion of the individual 7 high risk HPV types included in the vaccine varied by cytological and
histological grades of HPV-positive precancerous cervical lesions. HPV 16 was the dominant type in all
lesions, with contributions in low grade lesions ranging from 16.6%(14.3–19.2) in Mexico to 39.8% (30.0–
50.2) in India, and contributions in high grade lesions ranging from 43.8% (36.3–51.4) in Mexico to 64.1%
(60.6–67.5) in Brazil. After HPV 16, variations in other majors HPV types were observed by country, with
an under representation of HPV 18 and 45 compared to ICC.
Conclusion: The addition of HPVs 31/33/45/52/58 to HPV types included in current vaccines could
increase the ICC preventable fraction in a range of 12 to 19% across the four countries, accounting the
9-types altogether 90% of ICC cases. Assuming the same degree of efﬁcacy of current vaccines, the
implementation of the 9-valent HPV vaccine in Brazil, Mexico, India and China would substantially
impact on the reduction of the world cervical cancer burden.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Brazil, Mexico, India and China are currently considered among
the most populated and fastest growing emerging nations. By
2013, these four countries encompass 42% of the world’s
population, and hold a combined Gross Domestic Product (GDP)
(PPP) of 21.7 trillion dollars that represents 30% of the worldwide
GDP [1]. Since the four countries are developing rapidly, by 2050
their combined economies could eclipse the combined economies
of the current richest countries of the world [2].
Cervical cancer and other human papillomavirus (HPV) related
cancers represent an important global public health problem, both
in more and less developed countries. It is generally accepted that
persistent infection with high risk (HR) HPV is necessary for the
development of invasive cervical cancer (ICC) [3]. By 2011, the
International Agency for Research on Cancer (IARC) classiﬁed 12
HPV types as cervical carcinogens, including HPVs 16/18/31/33/
35/39/45/51/52/56/58 and 59 [4].
According to Globocan 2012, Brazil, Mexico, India and China
together contribute to 41% (n = 216 998) and 42% (n = 110 186) of
new diagnoses and deaths of ICC, respectively, occurring annually
worldwide, with the highest contribution observed in India and
China, where 184 535 and 97 003 new cases and deaths occur due
to ICC. ICC remains as the second most common female cancer in
three of the four countries, with the exception of China, were ICC is
the eighth in the ranking of female cancer. ICC is also the second
cause of female cancer deaths in Mexico and India, the fourth in
Brazil, and the seventh in China [5] (Fig. 1).
Estimated disability-adjusted life-years (DALYs) from ICC in
2008 were 334 per 100 000 persons per year in Brazil, 316 in
Mexico, 466 in India and 141 in China. China and India contributed
to more than 67% of the overall burden of DALYs lost because of ICC
in Asia, and Brazil and Mexico together contributed to 53% in Latin
America [6]. Differences in DALYs between countries indicate
substantial inequalities in prognosis after diagnosis, related to
degree of human development. This information is also very useful
for establishing priorities in ICC control, both in deciding available63 806 000 fem pop
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Fig. 1. Cervical cancer burden and sociodemographic indicators in Brazil, Mexico, India
CCI: Cervical Cancer Incidence; CCM: Cervical Cancer Mortality; ASR: Age Standardized Ra
cervical cancer incidence to other cancers among all women. Ranking is based on crud
References: [1]; [5]; [22].cervical cancer prevention strategies as well as prioritizing cervical
cancer control among other public health interventions.
Two safe and highly efﬁcacious HPV prophylactic vaccines are
currently available, a bivalent (CervarixTM) and a quadrivalent one
(Gardasil1), being the most effective intervention to control for
HPV and cervical cancer, particularly in developing countries [7].
Both vaccines prevent infection by HPVs 16/18, responsible for
about 70% ICC cases [8,9], and Gardasil1 also includes HPVs 6/11,
which cause close to 90% of external genital warts [10]. These
vaccines are close to 100% effective, against the vaccine types,
when administered in a 3 dose course, and thus, over 100 countries
have licensed the vaccine, and some have already included them in
their national immunization programs; especially developed
countries [11,12].
By June 2011, Brazil, Mexico and India had licensed both
vaccines, while China did not have any licensure yet (either
bivalent or quadrivalent) [13]. Mexico was among the ﬁrst middle
income countries to introduce HPV vaccine and by 2012 national
rollout of the vaccination program was achieved. Brazil is the other
country that is nowadays introducing the vaccine, planning to
achieve national rollout of the vaccination program by 2014
[14,15].
The greatest impact of HPV vaccination is expected in low-
income and middle-income countries (that includes the four
mentioned countries), where current HPV vaccines, without any
other preventive actions, are estimated to potentially reduce
cancer risk by 40–50% at 70% vaccine uptake [16,17].
Worldwide, HPV16 and 18, the two vaccine-preventable types,
contribute to over 70% of all cervical cancer cases. After HPVs 16/
18, the six most common HPV types are the same worldwide,
although its contribution varies by country and region. These HPV
types are namely 31/33/35/45/52 and 58; and account for an
additional 20% of cervical cancer cases [8,9]. Merck is developing
an investigational 9-valent HPV vaccine (V503), that similar to
current HPV vaccines, uses virus like particles (VLP). V503 contains
5 additional HPV types (31/33/45/52/58) to the 4 HPV types
previously included in Gardasil. Studies in women aged 16 to667 460 000 fem pop
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non-inferior to those generated by current quadrivalent vaccine,
with efﬁcacy against HPVs 31/33/45/52/58 related cervical/vulvar/
vaginal disease (any grade) of 97.1% (91.8–99.2) in the per protocol
efﬁcacy population [18].
Regional data on the prevalence and type distribution of HPVs is
essential for estimating the impact of vaccines on cervical cancer
and screening programs. The aim of the present article is to
estimate the proportion of disease caused by the 9-types included
in the investigational 9-valent HPV vaccine in order to evaluate its
potential impact in the reduction of the HPV-related cervical
disease burden in Brazil, Mexico, India and China, to help to
formulate recommendations on cervical cancer prevention.
2. Materials and methods
To estimate the proportion of the 7 HR HPV types included in
the V503 Merck’s investigational HPV vaccine, we used data from
an international study on HPV in ICC [8] and the most recent meta-
analysis in precancerous cervical lesions available in the literature
[19].
2.1. Cervical cancer
The estimations in ICC were based on data from a retrospective
cross-sectional study carried out at Catalan Institute of Oncology
(ICO), Spain in collaboration with DDL laboratory, The Netherlands,
to estimate the distribution of HPV types in women with ICC
diagnosed from 1949 to 2009 [8]. Brieﬂy, parafﬁn-embedded
specimens from consecutive ICC cases were obtained from hospital
pathology archives. After the blocks were processed, inclusion
criteria were a pathological conﬁrmation of a primary ICC of
epithelial origin in the tissue sample selected for analysis of HPV
DNA. HPV DNA detection was done by PCR with SPF-10 broad-
spectrum primers followed by DNA enzyme immunoassay and
genotyping with a reverse hybridization line probe assay - LiPA25
that detects 25 HR and low-risk (LR) HPV types (6, 11, 16, 18, 31, 33,
34,35, 39, 40, 42, 43, 44,45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, 74).
Sequence analysis was done to characterize HPV DNA-positive
samples with unknown HPV types. If no HPV type could be
attributed after sequencing, the HPV was labelled undetermined.
The study ﬁnally included information of 10 575 ICC cases from 38
countries, with 8 977 (85%) of them positive for HPV DNA. Data
extracted and used for the present report was of 540 cases (5.1% of
the total number of cases of the original series) from Brazil, 573Table 1
Characteristics of invasive cervical cancer cases included for HPV DNA detection in Bra
Brazil (N = 540) Mexico
Age at diagnosis (years)
Mean (95%CI) 54.3 (53.1–55.5) 48.1 
Histology - N (%)
SCC 455 (84.3) 505 (8
ADC 71 (13.1) 40 (7
ADSCC 5 (0.9) 22 (3
Others 9 (1.7) 6 (1
Period of diagnosis - N (%)
1960–1969 0 (0.0) 155 (2
1970–1979 119 (22.0) 139 (2
1980–1989 152 (28.1) 131 (2
1990–1999 240 (44.0) 115 (2
2000- 29 (5.4) 33 (5
HPV/DNA positivity - N (%)
HPV/DNA positivity 453 (83.9) 485 (8
‘‘N’’: Number of Invasive cervical cancer cases included in the study, ‘‘95%CI’’: 95% Conﬁd
Adenosquamous Cell Carcinoma; ‘‘Others’’: undifferentiated, neuroendocrine, not othe
(For more details, please see methodological section from [8]).cases (5.4%) from Mexico, 252 cases from India (2.4%) and 200
cases (1.9%) from China. Numbers of cases HPV DNA-positive by
country were 453 (83.9%) in Brazil, 485 (84.6%) in Mexico, 230
(91.3%) in India and 188 (94.0%) in China. General characteristics of
ICC included are provided in Table 1.
The proportion of the 7 HR HPV types included in the 9-valent
HPV vaccine (HPV 16/18/31/33/45/52/58) in ICC was expressed as
the proportion of women positive for a given type among the HPV-
positive samples. We did not include the proportion of HPVs 6/11
in the estimations because we did not ﬁnd a case with any single
infections by those types in these case collection. The availability of
HPV-disaggregated data allowed the calculation of proportions for
HPV types alone or for the groups of HPV types. Multiple infections
were added to single types in accordance with a proportional
weighting attribution [20,21]. For example, if two ICC lesions found
to test positive for both HPV 16 and 45 in one of the 4 countries,
and there were 9 cases infected by HPV-16 as a single type and 1
case infected by HPV 45 as a single type, then [2  9/(9 + 1)] or 1.8
of these two multi-type infected lesions would be attributed to
HPV 16 and [2  1/(9 + 1)] or 0.2 attributed to HPV 45. The
rationale of the proportional weighting attribution to assign
causality within mixed infection is based on assuming that the
probability of a particular HPV type detected in a mixed infection
to be the causative agent of the cancer is equivalent to the
positivity rate of this particular type among HPV positive ICC cases
infected with a single infection. This approach was selected based
on giving a higher weight to the types that are more frequently
found as single infections in invasive lesions.
The estimations were provided for the following histological
categories: Squamous Cell Carcinoma (SCC), Adenocarcinoma
(ADC), Adenosquamous Cell Carcinoma (ADSCC) and others
(undifferentiated, neuroendocrine, not otherwise speciﬁed, basal
adenoid and cystic adenoid carcinomas). The proportions by age
groups were also evaluated. These were estimated for the 7 HPV
types altogether and age groups were stratiﬁed by tertiles. The
main reason for these groups was the low number of cases
included in smaller age groups.
Projections of new ICC cases attributed to HPVs 16/18 and HPVs
31/33/45/52/58 were calculated for year 2013 and projected to
year 2025, worldwide and by country. Estimations were based on
the following assumptions and data sources: (a) It is generally
accepted that the presence of oncogenic HPV types are necessary
for the development of cervical cancer, so the contribution of HPV
types altogether is almost 100% [3]. Therefore, we assumed the
attributable fraction (AF) for each HPV type in ICC corresponded tozil, Mexico, India and China.
 (N = 573) India (N = 252) China (N = 200)
(47.0–49.1) 52.0 (50.7–53.3) 49.2 (47.6–50.9)
8.1) 237 (94.0) 191 (95.5)
.0) 9 (3.6) 7 (3.5)
.8) 1 (0.4) 0 (0.0)
.0) 5 (2.0) 2 (1.0)
7.1) 0 (0.0) 0 (0.0)
4.3) 0 (0.0) 0 (0.0)
2.9) 0 (0.0) 0 (0.0)
0.1) 0 (0.0) 200 (100.0)
.8) 252 (100.0) 0 (0.0)
4.6) 230 (91.3) 188 (94.0)
ence Interval, ‘‘SCC’’: Squamous Cell Carcinoma, ‘‘ADC’’: Adenocarcinoma, ‘‘ADSCC’’:
rwise speciﬁed, basal adenoid and cystic adenoid carcinomas.
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Sanjose´ and colleagues study was used as the world AF, without
weighting country estimations [8]; (b) Globocan 2012 age-speciﬁc
incidence rates were used with the assumption that these rates
will apply in the future [5]; (c) The population forecast for 2013
and 2025 available in the latest revision of the World Population
Prospects (2012 revision) was used [22]. Impact of vaccination was
not taken into account.
2.2. Precancerous cervical lesions
The estimation of proportions in precancerous cervical lesions
were based on data from a recent IARC meta-analysis including
information on HPV type distribution in 115 789 HPV-positive
women from 423 PCR-based studies worldwide [19]. Inclusion
criteria were: use of broad-spectrum consensus PCR-assays based
on the primers MY09/11, PGMY09/11, GP5+/6+, SPF10, SPF1/GP6
or L1C1/L1C2, and information of overall and type-speciﬁc HPV
prevalence, by strata of cyto- and/or histo-pathological cervical
diagnoses. For the present report, data were extracted from 38
studies from Brazil, Mexico, India and China that yield 6 025 HPV-
positive cases (5.2% of the total number of cases) (a summary of the
studies included and information on number of cases retrieved
from the meta-analysis are listed in Table 1 of supplementary
material). Information was provided for 1 809 cases (72.3% HPV
DNA-positive) of low-grade squamous intraepithelial lesions
(LSIL), and 945 cases (73.0% HPV DNA-positive) of high-grade
SIL (HSIL) diagnosed cytologically; 2 168 cases (65.9% HPV DNA-
positive) of cervical intraepithelial neoplasia grade 1 (CIN1), 1 466
cases (78.2% HPV DNA-positive) of CIN2 and 1 750 cases (82.5%
HPV DNA-positive) of CIN3 diagnosed histologically. Although
cytological data (LSIL, HSIL) was available for the four mentioned
countries, data for the full range of histological diagnosis (CIN1,
CIN2, CIN3) was only available for Brazil and China (only CIN1 data
was provided for Mexico and India).
The contribution of the 7 HR individual HPV types (16/18/31/
33/45/52/58) was expressed as the proportion of samples positive
for a given type among all the HPV-positive samples tested for the
mentioned type, therefore denominators varied by genotype.
Individual-level data on HPV types in multiple infections were not
available, so proportions include single and multiple infections and
the total sum can exceed 100% [19]. We did not include proportions
of HPVs 6/11 because the data source did not give speciﬁc
information for those HPVs. In order to try to retain appropriate
sample size for comparisons among countries, precancerousTable 2
Contribution of HPVs 16/18/31/33/45/52/58 in cases of invasive cervical cancer that te
HPV Type Brazil (N = 453) % (95%CI) Mexico (N = 48
Combinations of HPV types
7 HPV typesa 88.6 (85.2–91.3) 85.7 (82.3–88.
HPV 16/18 69.7 (65.3–74.0) 68.2 (63.9–72.
HPV 31/33/45/52/58 18.8 (15.3–22.7) 17.6 (14.5–21.
Other types 11.4 (8.7–14.8) 14.3 (11.2–17.
Speciﬁc HPV types
HPV 16 61.6 (56.9–66.1) 56.3 (51.7–60.
HPV 18 8.1 (5.8–11.1) 11.9 (9.2–15.2
HPV 31 3.1 (1.7–5.1) 4.2 (2.5–6.3) 
HPV 33 5.2 (3.2–7.5) 2.2 (1.0–3.8) 
HPV 45 6.9 (4.7–9.6) 6.4 (4.4–9.0) 
HPV 52 2.5 (1.2–4.3) 1.5 (0.7–3.2) 
HPV 58 1.1 (0.4–2.6) 3.3 (1.9–5.3) 
‘‘95%CI’’: 95% Conﬁdence Interval (one-sided, 97.5%CI calculated when appropriate); ‘‘N
Additional information: Available data are from unvaccinated women (pre-vaccinatio
attribution of multiple types; Denominator = HPV/DNA positive cervical cancer cases fo
a ‘‘7 HPV types’’ includes the HR HPV types ones in 9-valent HPV vaccine: HPVs 16/cervical lesions were collapsed in two categories; Low-grade,
encompassing LSIL and CIN1; and High-grade, including HSIL, CIN2
and CIN3. However, in supplementary material we show the
proportion of HPV types by histologically conﬁrmed CIN1, 2, 3
cases by country.
3. Results
3.1. Cervical cancer
Combined contribution of the 7 HR HPV types included in the 9-
valent HPV vaccine (HPVs 16/18/31/33/45/52/58) was higher in
Asian countries than Latin-American ones, with 97.3% (93.9–99.1)
in China, 92.2% (87.9–95.3) in India, 88.6% (85.2–91.3) in Brazil,
and 85.7% (82.3–88.8) in Mexico. HPV type distribution varied by
country. Although HPVs 16/18 were the most common types,
important differences in their contribution were observed
(p < 0.001), with higher proportions in China and India (85.5%
(79.8–90.3) and 80.8% (75.2–85.7), respectively), compared to
Brazil and Mexico (69.7% (65.3–74.0) and 68.2% (63.9–72.4),
respectively). In opposition, the additional proportion of the other
5 high risk HPV types (HPVs 31/33/45/52/58) was higher in Brazil
and Mexico (18.8% (15.3–22.7) and 17.6% (14.2–21.2), respective-
ly) compared to India and China (11.3% (7.5–16.1) and 11.9% (7.5–
17.2), respectively). Infections by HPV types different to those
included in the 9-valent HPV vaccine were more usually detected
in Brazil and Mexico (11.4% (8.7–14.8) and 14.3% (11.2–17.7) than
India and China 7.8% (4.7–12.1) and 2.7% (0.9–6.1), where lower
proportions were observed (Table 2). Compared to the other 3
countries, the observed distribution of the 7 HPV types in Brazil
was the most similar to that observed worldwide (Fig. 2).
HPV 45 was the most frequently detected type after HPV 16 and
18 in either Brazil and Mexico being 6.9% (4.7–9.6) and 6.4% (4.4–
9.0) respectively, and followed by HPV 31 and 33 (ranging from
2.1% to 5.2%) in ICC cases. In Asian countries, HPV 52/58 were
especially prominent in China (2.7% (0.9–6.1) and 4.4% (1.9–8.2),
respectively) compared to a higher contribution of HPVs 31/33 and
45 in India (ranging from 2.6% to 3.5%). Addition of low risk HPVs 6/
11 did not modify the cancer burden estimates because we did not
ﬁnd any case with single infection.
The 7 HR HPV types altogether accounted for 85.0% in all
histological diagnosis, with higher contributions in ADC, ADSCC
and other histologies (including undifferentiated, neuroendocrine,
not otherwise speciﬁed, basal adenoid and cystic adenoid
carcinomas) compared to SCC. As previously observed, HPV 16sted positive for any HPV, in Brazil, Mexico, India and China.
5) % (95%CI) India (N = 230) % (95%CI) China (N = 188) % (95%CI)
8) 92.2 (87.9–95.3) 97.3 (93.9–99.1)
4) 80.8 (75.2–85.7) 85.5 (79.8–90.3)
2) 11.3 (7.5–16.1) 11.9 (7.5–17.2)
7) 7.8 (4.7–12.1) 2.7 (0.9–6.1)
8) 72.5 (66.4–78.3) 81.7 (75.7–86.1)
) 8.3 (5.0–12.6) 3.8 (1.5–7.5)
2.6 (1.0–5.6) 1.1 (0.1–3.8)
3.5 (1.5–6.7) 2.7 (0.9–6.1)
3.1 (1.2–6.2) 1.1 (0.1–3.8)
0.4 (0.0–2.4) 2.7 (0.9–6.1)
1.7 (0.5–4.4) 4.4 (1.9–8.2)
’’: Invasive cervical cancer cases that tested positive for HPV DNA.
n period). Type speciﬁc estimations: Numerator = single infections + proportional
r any type (for more details, please see methodological section from [8]).
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Fig. 2. Contribution of HPVs 16/18/31/33/45/52/58 in cases of invasive cervical cancer that tested positive for HPV DNA, in Brazil, Mexico, India and China compared to the
worldwide HPV type distribution.
Additional information: Available data are from unvaccinated women (pre-vaccination period). Type speciﬁc estimations: Numerator = single infections + proportional
attribution of multiple types; Denominator = HPV/DNA positive cervical cancer cases for any type (for more details, please see methodological section from [8]).
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categories, followed by HPVs 18 and 45. Greater contributions
of HPVs 18 and 45 were observed in histologies different to SCC
(Table 3).Table 3
Contribution of HPVs 16/18/31/33/45/52/58 in cases of invasive cervical cancer that te
SCC AD
Country HPV % (95%CI) % 
Brazil Any HPV (N) 404 37
HPV 16 62.2 (57.2–66.9) 56
HPV 18 6.6 (4.5–9.6) 18
HPV 31 3.3 (1.7–5.4) 2
HPV 33 5.6 (3.4–8.1) 0
HPV 45 6.2 (4.0–9.0) 16
HPV 52 2.8 (1.4–4.8) 0
HPV 58 1.3 (0.4–2.9) 0
Other HPV 12.1 (9.1-15.7) 5
Mexico Any HPV (N) 433 29
HPV 16 56.6 (51.8–61.3) 55
HPV 18 11.2 (8.3–14.4) 13
HPV 31 3.9 (2.3–6.2) 6
HPV 33 2.2 (1.0–3.9) 3
HPV 45 5.5 (3.6–8.1) 15
HPV 52 1.7 (0.8–3.6) 0
HPV 58 3.4 (2.0–5.6) 0
Other HPV 15.4 (12.2–19.2) 5
India Any HPV (N) 220 5
HPV 16 73.1 (66.8–78.9) 60
HPV 18 6.9 (3.9–11.0) 40
HPV 31 2.7 (1.0–5.8) 0
HPV 33 3.6 (1.6–7.0) 0
HPV 45 3.2 (1.3–6.5) 0
HPV 52 0.5 (0.0–2.5) 0
HPV 58 1.8 (0.5–4.6) 0
Other HPV 8.2 (4.9–12.6) 0
China Any HPV (N) 181 5
HPV 16 82.1 (76.0–87.6) 60
HPV 18 2.8 (0.9–6.3) 40
HPV 31 1.1 (0.1–3.9) 0
HPV 33 2.8 (0.9–6.3) 0
HPV 45 1.1 (0.1–3.9) 0
HPV 52 2.8 (0.9–6.3) 0
HPV 58 4.6 (1.9–8.5) 0
Other HPV 2.8 (0.9–6.3) 0
‘‘95%CI’’: 95% Conﬁdence Interval (one-sided, 97.5%CI calculated when appropriate), ‘‘SC
cell carcinoma, ‘‘Others’’ includes undifferentiated, neuroendocrine, not otherwise spec
Additional information: Available data are from unvaccinated women (pre-vaccinatio
attribution of multiple types; Denominator = HPV/DNA positive cervical cancer cases foAnalysis for individual HPV types by age was not possible due to
the low number of cases included in each group. Overall proportion
of the 7 HR types altogether decreased with age in India, Mexico
and Brazil and increased in China, however the low number ofsted positive for any HPV, by histology, in Brazil, Mexico, India and China.
C ADSCC Others
(95%CI) % (95%CI) % (95%CI)
 4 8
.1 (39.5–72.9) 50.0 (6.8–93.2) 62.5 (24.5–91.5)
.9 (8.0–35.2) 0.0 (0.0–60.2) 37.5 (8.5–75.5)
.7 (0.1–14.2) 0.0 (0.0–60.2) 0.0 (0.0–36.9)
.0 (0.0–9.5) 25.0 (0.6–80.6) 0.0 (0.0–36.9)
.8 (6.2–32.0) 0.0 (0.0–60.2) 0.0 (0.0–36.9)
.0 (0.0–9.5) 0.0 (0.0–60.2) 0.0 (0.0–36.9)
.0 (0.0–9.5) 0.0 (0.0–60.2) 0.0 (0.0–36.9)
.4 (0.7–18.2) 25.0 (0.6–80.6) 0.0 (0.0–36.9)
 18 5
.2 (35.7–73.6) 54.2 (30.8–78.5) 40.0 (5.3–85.3)
.8 (3.9–31.7) 16.7 (3.6–41.4) 40.0 (5.3–85.3)
.9 (0.8–22.8) 5.6 (0.1–27.3) 0.0 (0.0–52.2)
.4 (0.1–17.8) 0.0 (0.0–18.5) 0.0 (0.0–52.2)
.5 (5.8–35.8) 12.0 (1.4–34.7) 20.0 (0.5–71.6)
.0 (0.0–11.9) 0.0 (0.0–18.5) 0.0 (0.0–52.2)
.0 (0.0–11.9) 6.0 (0.1–27.3) 0.0 (0.0–52.2)
.2 (0.8–22.8) 5.6 (0.1–27.3) 0.0 (0.0–52.2)
 1 4
.0 (14.7–94.7) 100.0 (2.5–100.0) 50.0 (6.8–93.2)
.0 (5.3–85.3) 0.0 (0.0–97.5) 50.0 (6.8–93.2)
.0 (0.0–52.2) 0.0 (0.0–97.5) 0.0 (0.0–60.2)
.0 (0.0–52.2) 0.0 (0.0–97.5) 0.0 (0.0–60.2)
.0 (0.0–52.2) 0.0 (0.0–97.5) 0.0 (0.0–60.2)
.0 (0.0–52.2) 0.0 (0.0–97.5) 0.0 (0.0–60.2)
.0 (0.0–52.2) 0.0 (0.0–97.5) 0.0 (0.0–60.2)
.0 (0.0–52.2) 0.0 (0.0–97.5) 0.0 (0.0–60.2)
 0 2
.0 (14.7–94.7) – 100.0 (15.8–100.0)
.0 (5.3–85.3) – 0.0 (0.0–84.2)
.0 (0.0–52.2) – 0.0 (0.0–84.2)
.0 (0.0–52.2) – 0.0 (0.0–84.2)
.0 (0.0–52.2) – 0.0 (0.0–84.2)
.0 (0.0–52.2) – 0.0 (0.0–84.2)
.0 (0.0–52.2) – 0.0 (0.0–84.2)
.0 (0.0–52.2) – 0.0 (0.0–84.2)
C’’: Squamous Cell Carcinoma, ‘‘ADC’’: Adenocarcinoma, ‘‘ADSCC’’: Adenosquamous
iﬁed, basal adenoid and cystic adenoid carcinomas.
n period). Type speciﬁc estimations: Numerator = single infections + proportional
r any HPV (for more details, please see methodological section from [8]).
B. Serrano et al. / Cancer Epidemiology 38 (2014) 748–756 753cases included for each country can lead to instability in the
estimates (data not shown).
Without changes in prevention and control, and only due to
population growth, projections for the next years reveal a growing
burden of cervical cancer in the four countries. Projected global
estimates of ICC cases in these countries, not taking into account
the impact of vaccination and assuming that all cases are related to
HPV infection, are expected to rise to 241 620 new cases in 2025,
with 193 949 cases attributable to HPVs 16/18 and 30 320 cases
attributable to HPVs 31/33/45/52/58. Brazil, Mexico, India and
China will contribute to over 40% of the world ICC cases, and almost
35% of cases diagnosed only in India and China (Table 4).
3.2. Precancerous cervical lesions
Contribution of the individual HPV types varied by cytological
and histological grade of HPV-positive precancerous cervical
lesions in the mentioned countries.
Overall, HPV-positivity for any type in the combined four
countries gradually increased with the severity of cervical disease,
from 68.8% in low-grade cervical lesions (including LSIL and CIN1)
to 78.9% in high-grade lesions (including HSIL, CIN2 and CIN3).
HPV 16 was the most predominant type in all grades of cervical
lesions in the four countries, with an increasing prevalence with
greater diagnosis severity. Proportion of HPV16 in HPV-positive
low-grade lesions ranged from 16.6% (14.3–19.2) in Mexico to
39.8% (30.0–50.2) in India, and proportions in high-grade lesions
ranged from 43.8% (36.3–51.4) in Mexico to 64.1% (60.6–67.5) in
Brazil. After HPV 16, variations in the second most frequent HPV
type by country were observed. Regarding HPV-positive high-
grade lesions, HPV 31 was the second most detected type in Brazil
(12.0%) and India (17.7%), vs HPV 58 in Mexico (11.8%), and HPVs
52/58 in China (22.4% and 18.1%, respectively)(Table 5).
Regarding cytological lesions, only HPV 16 clearly increased
with lesion severity in the four countries, with higher contribu-
tions in HSIL lesions compared to LSIL. Contribution of other HPV
types varied by country but also by cytological diagnosis.
Similar situation was observed for histological diagnosis (only
possible in China and Brazil where data for CIN1, CIN2 and CIN3
were provided; Data on HPV types contribution by histologically
conﬁrmed grades is shown in Table 2 of supplementary material).
HPV 16 was the only type with a signiﬁcant increase with lesion
severity. Distribution of the other HPV types not only did not
uniformly increase but even decreased by lesion severity.
Combined estimations of HPV types altogether for precancer-
ous cervical lesions, similar to that in ICC, was not possible becauseTable 4
Burden of cervical cancers attributable to HPV infection in 2013, projected to 2025; in
Area HPV (%) Attributable new cases
Year 2013 
16/18 31/33/45/52/58 Total ICC 16/18 
World 70.8 18.5 536 299 379 64
Brazil 69.7 18.8 18 738 13 06
Mexico 68.2 17.6 14 946 10 08
India 80.8 11.3 122 150 98 73
China 85.5 11.9 62 741 53 62
Total (4 countries) 218 575 175 61
‘‘ICC’’: Invasive Cervical Cancer.
Additional information: We assume that almost all cervical cancer cases are caused by H
infection ([3]).
Estimated numbers of new invasive cervical cancer cases diagnosed are based on [5]; [22
[8].
Impact of vaccination has not been taken into account for the calculations of 2025 pro
Speciﬁc information on HPV 6 and 11 is not included due to low relative contributiononly a few articles from Guan meta-analysis provided detailed
information for single and multiple infections in the mentioned
countries.
4. Discussion
This analysis aimed to estimate type distribution of the 9 HPV
types included in an investigational broad spectrum vaccine
currently under development across different grades of cervical
lesions for Brazil, Mexico, India and China. Although existing
vaccines cover HPVs 16/18, responsible for 70% of ICC worldwide,
the inclusion of other HR HPV types named 31/33/45/52/58 would
increase the protection to almost 90% of the infections responsible
for ICC. Our ﬁndings conﬁrmed these data. The incremental
preventable fraction added by the new HPV vaccine to the current
ones ranged from 12% to 19% across the four countries with a lower
proportion of ICC potentially preventable by the 9-valent vaccine
observed in Latin American countries than in the Asian ones [8,9].
It should be noted that the 9-valent HPV vaccine could achieve
protection over 95% in China, while current HPV vaccines achieve
protection of 85% (against HPVs16/18) in this country [9,23].
HPV 16 is uniformly reported as the most common HPV type in
all histological subtypes of ICC worldwide. As previously described,
our data conﬁrmed regional variations in the proportion of ICC due
to each speciﬁc HPV type [8,9,19]. Similar to other countries in East
Asia, HPVs 52 and 58 had a prominent role in China where these
types were identiﬁed in more than 7% of cases [9,24,25]. HPV 45
was more common in Brazil and Mexico (more than 6% of cases)
and HPV33 accounted for more than 5% of cases in Brazil [9,26,27].
Finally, a wide variety of HPV types were observed in India with
HPV 33 being slightly more prominent than others [28,29].
It should be noted that although the contribution of the 7 HR
types altogether was higher in Asian countries, it was the result of
the high prevalence of HPVs 16 and 18. By contrast, a remarkable
contribution of the new 5 types included in the 9-valent HPV
vaccine was observed in Latin American countries, where the use of
the 9-valent HPV vaccine could increase HPV preventable fraction
in more than 10% [9].
Our data supported HPV 16 as the most common type in ICC,
being HPV18 consistently the second most detected type in the
four countries [9,26,30,31]. Although HPV16 was the most
commonly detected type in HPV-positive women with precancer-
ous cervical lesions, HPV18 and 45 were underrepresented
compared to the high contribution in ICC, and other HPV types
gained prominence but varied by country. HPV 31 was more
usually observed in India and Brazil and HPV 52 in China either in Brazil, Mexico, India and China compared to the world.
 (in thousands)
Year 2025
31/33/45/52/58 Total ICC 16/18 31/33/45/52/58
6 99 215 605 283 428 480 111 977
8 3 528 20 422 14 242 3 845
9 2 623 16 827 11 471 2 953
4 13 852 138 799 112 192 15 740
5 7 447 65 572 56 044 7 783
5 27 450 241 620 193 949 30 320
PV infection, and thus almost 100% of cervical cancer cases are attributable to HPV
]. HPV type-speciﬁc proportions for the world and countries are based on data from
jections.
 of these types.
Table 5
Contribution of HPVs 16/18/31/33/45/52/58 in women with precancerous cervical lesions that tested positive for any HPV, in Brazil, Mexico, India and China.
Country HPV type Low grade lesions High grade lesions
N % 95%CI N % 95%CI
Brazil HPV 16 334 33.5 (28.5–38.9) 769 64.1 (60.6–67.5)
HPV 18 332 11.1 (8.0–15.0) 759 8.8 (6.9–11.1)
HPV 31 272 14.7 (10.7–19.5) 682 12.0 (9.7–14.7)
HPV 33 264 5.3 (2.9–8.7) 617 6.5 (4.7–8.7)
HPV 45 223 4.9 (2.5–8.7) 679 6.2 (4.5–8.3)
HPV 52 215 11.2 (7.3–16.2) 614 6.2 (4.4–8.4)
HPV 58 310 13.2 (9.7–17.5) 652 8.1 (6.2–10.5)
Mexico HPV 16 922 16.6 (14.3–19.2) 176 43.8 (36.3–51.4)
HPV 18 922 4.8 (3.5–6.4) 176 9.1 (5.3–14.3)
HPV 31 922 2.3 (1.4–3.5) 176 9.1 (5.3–14.3)
HPV 33 866 12.2 (10.1–14.6) 161 8.7 (4.8–14.2)
HPV 45 866 3.4 (2.3–4.8) 161 1.9 (0.4–5.4)
HPV 52 866 1.2 (0.6–2.1) 161 1.2 (0.2–4.4)
HPV 58 866 3.6 (2.4–5.0) 161 11.8 (7.3–17.8)
India HPV 16 98 39.8 (30.0–50.2) 79 59.5 (47.9–70.4)
HPV 18 98 11.2 (5.7–19.2) 79 16.5 (9.1–26.5)
HPV 31 23 17.4 (5.0-38.8) 17 17.7 (3.8–43.4)
HPV 33 23 4.4 (0.1–22.0) 17 11.8 (1.5–36.4)
HPV 45 23 0.0 (0.0–14.8) 17 5.9 (0.2–28.7)
HPV 52 23 4.4 (0.1–22.0) 17 0.0 (0.0–19.5)
HPV 58 23 8.7 (1.1–28.0) 17 5.9 (0.2–28.7)
China HPV 16 1 382 24.4 (22.1–26.7) 2 265 47.6 (45.6–49.7)
HPV 18 1 382 9.5 (8.0–11.2) 2 265 9.1 (8.0–10.4)
HPV 31 1 382 6.0 (4.8–7.4) 2 265 6.5 (5.5–7.6)
HPV 33 1 382 8.3 (6.9–9.9) 2 265 8.9 (7.7–10.1)
HPV 45 1 382 0.9 (0.5–1.6) 2 214 2.1 (1.6–2.8)
HPV 52 1 382 20.8 (18.7–23.1) 2 214 22.4 (20.6–24.2)
HPV 58 1 382 17.6 (15.6–19.7) 2 214 18.1 (16.5–19.7)
Low-grade, includes LSIL and CIN1; High-grade, includes HSIL, CIN2 and CIN3
‘‘N’’: HPV positive cases tested for the speciﬁc HPV type;‘‘95%CI’’: 95% Conﬁdence Interval (one-sided, 97.5%CI calculated when appropriate).
Additional information: Type speciﬁc estimations: Numerator = includes either single or multiple infections, thus the total sum of % can exceed 100%; Denominator = ‘‘Tested’’
cases that stands for the HPV/DNA positive cases for any type from studies testing for the HPV type in question, thus denominators vary by type.
Data from [19].
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frequently detected in low grade lesions and HPV 58 in high grade
lesions [23,24,27,30].
Similar to previous ﬁndings a greater contribution of HPV 18
was observed in ADC, ADSCC, and other histologies (such as
neuroendocrine tumours) compared to SCC and conversely, HPV
16 proportion was higher in SCC [9,32]. In agreement with the
world distribution, higher rates of protection with the 9-valent
HPV vaccine could be expected for these histologies in the four
countries. Due to the limited number of cases included for each
histological category, data should be interpreted cautiously and
further research to provide solid estimations is needed.
Multiple infections complicate the estimation of the attribution
of cases to HPV types. Contribution of multiple infections was only
possible for ICC lesions, where multiple infections were added to
single types in accordance with a proportional weighting attribu-
tion. A more conservative estimation was performed by combining
single type infections and multiple type infections restricted to the
exact combination of the 7 HR mentioned types thus excluding
cases with at least one HPV type not included in the 9-valent
vaccine. The proportions obtained ranged from 80% in Mexico, 84%
in Brazil, 91% in India and 94% in China, meaning that the HPV
types included in the 9-valent HPV vaccine could still cover an
important amount of infections responsible for ICC if we use a
more restrictive deﬁnition in the estimations.
Although multiple infections were more usually diagnosed in
earlier stages of cervical pre-neoplastic lesions in the mentioned
countries (articles reporting prevalence of multiple infections
accounted 21–52% multiple infections for CIN1; 18–51% for CIN2;
16–32% for CIN3; compared to 6.9–7.1% in ICC) [8,19], no similar
attribution of multiple infections was possible for precancerous
cervical lesions, meaning that HPV positive women with multipleinfections were counted more than once. Hence estimations for
precancerous lesions were shown only for individual, and not
combinations of HPV types. Although this approach does not allow
to estimate type speciﬁc risk, it can be useful to identify HPV
variations among country and lesion severity, and also to detect
populations at a higher risk for cancer progression, as it has been
conﬁrmed that viral persistence of HPV16 and 18 is less likely to
regress than other HPV types [33].
CIN2/3 lesions rarely occur in absence of HR HPV infections but
this has not been conﬁrmed in lower grades of cervical lesions [34].
Data from Guan et al. meta-analysis revealed that less than 70% of
CIN1 or LSIL cases were positive for any HPV compared to a close to
80% positivity in CIN2/3 or HSIL lesions. Solid estimations
considering single and combinations of HPV types cannot be
provided, unless individual data on single and multiple infections
are available.
For estimations of HPV attributable cases, we assumed that
Globocan 2012 incidence rates will apply in the future, and
calculated expected numbers using the appropriate population
forecast [5,22]. Impact of screening and vaccination programs in
these countries was not taken into account. It should be
emphasized that although one of every 3 cervical cancer patients
in the world is an Indian or Chinese women, both countries
remarkably lack cervical cancer screening programs and they are
far to achieve a broad spread screening practice [30,35,36]. The
large burden of ICC cases observed in both countries has not yet
sufﬁciently seized the attention of public health authorities and
the absolute burden is expected to increase in the future if effective
prevention measures are not undertaken. By contrast national
screening programs have been launched in Mexico and Brazil since
1974 and 1998, respectively [37,38]. Even with the efforts to
introduce organized screening programs, only a slight reduction in
B. Serrano et al. / Cancer Epidemiology 38 (2014) 748–756 755ICC mortality has been observed in both countries. Recent reports
indicate that other screening tools, like HPV testing, could be more
cost effective, than cervical cytology in these countries [39].
Particularly for HPV vaccines it has to be taken into consideration
that impact of vaccination programs on the reduction of invasive
lesions will need more than ten years to be observable. According
to WHO registries, HPV vaccination programs were implemented
in Mexico in 2008 and Brazil in 2012 (both countries with a
projected national rollout of the vaccination program in 2012), but
are not yet introduced in China or India [14]. Studies from Latin
America indicate that HPV vaccination only or supplemented with
screening may be a cost-effective strategy to reduce mortality by
cervical cancer [39]. Irrespective of changing risk, demographic
changes will have a major impact on the future burden of ICC and
this will be especially remarkable in developing countries where,
in general incidence and mortality rates have been relatively stable
over decades, reﬂecting the lack of screening implementation [40].
Present estimates can help decision-makers evaluate the potential
impact of existing and future vaccines in Brazil, Mexico, India and
China, providing an estimation of the HPV related cancer that could
be avoided if the population become immune to the types included
in the vaccine.
Data from previous reports conﬁrm that irrespective of
histological type, HPVs 16/18/45 are generally identiﬁed in
younger women more than other HPV types in all the world
regions. The number of ICC included in each country did not allow
us to stratify by country and age group. Our data suggest that the
distribution of the types altogether varies by country, with
increasing proportions observed in older ages in China, and
descending trends in the other 3 countries. Even though, it should
be mentioned that our data belong to speciﬁc centres (‘‘Hospital Dr
He´lioAngotti–Uberaba, Brazil’’; ‘‘Cancer Institute, Chinese Acade-
my of Medical Sciences and Peking Union Medical College –
Beijing, China’’; ‘‘Prevention and Relief Society – Raipur, India’’ and
‘‘Hospital General de Mexico – Mexico DF, Mexico) that may not be
representative of the whole territory. However, comparing the age
distribution of ICC cases for each country with the ones estimated
in GLOBOCAN 2012 only slight differences in the age-distribution
were found, reducing the impact of a potential age of diagnosis bias
(the main difference found was a lower proportion of ICC cases
from the youngest and eldest age groups in our Brazilian series).
Moreover, the good concordance of overall and type-speciﬁc HPV
estimations with previous reports suggests the representativeness
of the data included in the article. Observed HPV DNA positivity for
any type for ICC was 83.9% in Brazil, 84.8% in Mexico, 90.5% in India
and 94.0% in China, close to the positivity estimated in the most
recent IARC meta-analysis on ICC available in the literature [9].
Given that HPV is accepted as a necessary cause of ICC, the
negativity of both studies is expected to be related to technical
reasons, but also to the quality of the biological specimen.
A potential limitation for comparing HPV type-speciﬁc estima-
tions in cervical cancer between the four countries could be that
the period of diagnosis of cases is variable, with India and China
having representation of more recent cases, conversely Mexico and
Brazil covered a much broader period of time at diagnosis.
However, we expect that the impact will be minor, since we have
already published an analyses of the HPV types time trend
distribution by some speciﬁc countries included in the overall
study (that includes Brazil and Mexico), and we have not observed
statistically signiﬁcant trends overtime of diagnosis of the HPV
types included in the current HPV vaccines [41].
In the present work, we have selected Brazil, Mexico, China and
India since they are emerging economies that encompasses over
42% of the world’s population. Thus the cervical cancer prevention
in these countries would largely impact the world’s burden of the
disease. One limitation could be the exclusion of other countrieslike African. These were not the objective of this report, although
cervical cancer incidence rates in the sub-Saharan region are the
highest in the world. However, in a recent review of the HPV
burden in Sub-Saharan region it is showed that HPV16 and 18 are
also the most common genotypes in cervical cancer in these
countries [42]. Moreover, in a previous publication on the potential
impact of the 9-types vaccines in cervical cancer based in de
Sanjose´ and colleagues [8] cervical cancer study we did not ﬁnd
differences in the proportion of the 9-types in cervical cancer
specimens from Africa (87%), compared to the worldwide
estimation (89%) [43].
The 7 HR types included in the 9-valent vaccine had a notable
contribution in pre-neoplastic lesions in the four countries, thus
the vaccination would result in a reduced number of pre-
neoplastic lesions related to the included types and a reduction
of the treatment burden derived. Moreover, the addition of HPVs
31/33/45/52/58 to HPV types included in current vaccines could
increase the ICC preventable fraction in a range of 12 to 19% across
the four countries, accounting the 9-types altogether 90% of ICC
cases. The low proportion of cases attributable to HPV types not
included in the 9-valent HPV vaccine suggest that if this broad
spectrum vaccine achieves the same degree of efﬁcacy as previous
vaccines, ICC incidence rates could be substantially reduced in
these four countries and, consequently, worldwide.
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